- Editorial
- Atezolizumab and bevacizumab for hepatocellular carcinoma: how to approach salvage therapy for non-responders?
-
Naoshi Nishida
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi Osaka-Sayama, 589-8511, Japan
- Corresponding author: Naoshi Nishida ,Tel: +81-72-366-0221 (Ext. 3525), Fax: +81-72-367-2880, Email: naoshi@med.kindai.ac.jp
- Received: May 2, 2024; Accepted: May 3, 2024.